NCCN biosimilars white paper: Regulatory, scientific, and patient safety perspectives

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 9, Issue SUPPL. 4, 2011, Pages

  Zelenetz, Andrew D ^a   Ahmed, Islah ^b   Braud, Edward Louis ^c   Cross, James D ^d   Davenport Ennis, Nancy ^e   Dickinson, Barry D ^f   Goldberg, Steven E ^g   Gottlieb, Scott ^h   Johnson, Philip E ^j   Lyman, Gary H ^k   Markus, Richard ^l   Matulonis, Ursula A ^m   Reinke, Denise ⁿ   Li, Edward C ^o   DeMartino, Jessica ^o   Larsen, Jonathan K ^o   Hoffman, James M ⁱ  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Hospira   (United States)

^c Springfield Regional Cancer Center   (United States)

^d AETNA   (United States)

^e National Patient Advocate Foundation   (United States)

^f AMERICAN MEDICAL ASSOCIATION   (United States)

^g Express Scripts   (United States)

^h AMERICAN ENTERPRISE INSTITUTE   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^k DUKE CANCER INSTITUTE   (United States)

^l Amgen Global Development   (United States)

^m DANA FARBER CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^o NONE

more..

Author keywords

Biosimilars; Follow on biologics; Health policy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; DOCETAXEL; DOXORUBICIN; FULVESTRANT; GEMCITABINE; INTERFERON; IXABEPILONE; LEUPRORELIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB;

B CELL LYMPHOMA; BIOLOGICAL THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CONSENSUS DEVELOPMENT; COST CONTROL; DRUG APPROVAL; DRUG INDICATION; DRUG SAFETY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; LARGE CELL LYMPHOMA; LAW; MEDICAL PRACTICE; MOLECULAR CLONING; NEUTROPENIA; OFF LABEL DRUG USE; PATIENT EDUCATION; PATIENT SAFETY; PRACTICE GUIDELINE; PRESCRIPTION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SYNTHESIS; REVIEW; STANDARDIZATION; UNITED STATES;

EID: 80054922640     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2011.0136     Document Type: Review

References (33)

1. Patient Protection and Affordable Care Act of 2009, Pub. L. No. 111-148, Title VII, Subtitle A "Biologics Price Competition and Innovation Act of 2009," §7001-7003.
2. Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010;85:771-780.
3. Niederwieser D, Schmitz S. Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011;86:277-288.
4. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-419. (Pubitemid 351325660)
5. European Medicines Agency. Questions and answers on biosimilar medicines (similar biological medicinal products). Available at: http://www.emea.europa. eu/pdfs/human/pcwp/7456206en.pdf. Accessed June 2, 2011.
6. Schellenkens H, Moors E. Clinical comparability and European biosimilar regulations. Nat Biotechnol 2010;28:28-31.
7. European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2010/11/WC500099361.pdf. Accessed June 23, 2011.
8. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available at: http://www.who.int/biologicals/ areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. Accessed June 23, 2011.
9. Roger SD. Biosimilars: current status and future directions. Expert Opin Biol Ther 2010;10:1011-1018.
10. Public Health Service Act, 42 USC §262 (1944). "Regulation of Biological Products."
11. Gottlieb S. Biosimilars: policy, clinical, and regulatory considerations. Am J Health Syst Pharm 2008;65(14 Suppl 6):S2-8. (Pubitemid 352000712)
12. U.S. Food and Drug Administration. Rituximab: product approval information. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/1997/ritugen112697L.htm. Accessed May 10, 2011.
13. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-626.
14. Hudis C. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
15. Crawford J, Allen J, Armitage J, et al. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors. Version 1, 2011. Available at: http://www.nccn.org/professionals/physician-gls/pdf/myeloid-growth.pdf. Accessed March 4, 2011.
16. Doloresco F, Fominaya C, Schumock GT, et al. Projecting future drug expenditures - 2011. Am J Health Syst Pharm 2011;68:921-932.
17. Malik NN. Controlling the cost of innovative cancer therapeutics. Nat Rev Clin Oncol 2009;6:550-552.
18. Generic Pharmaceutical Association. Savings achieved through the use of generic pharmaceuticals 2000-2009. Available at: http://www.gphaonline.org/ sites/default/files/ GPhA%20Savings%20Study%20Book%20Updated%20Web%20FINAL%20Jul23%2010-0.pdf. Accessed May 12, 2011.
19. Congressional Budget Office. Congressional Budget Office Cost Estimate - S. 1695 Biologics Price Competition and Innovation Act of 2007. Available at: http://www.cbo.gov/ftpdocs/94xx/doc9496/s1695.pdf. Accessed May 12, 2011.
20. Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007;30:267-272. (Pubitemid 47482057)
21. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v4-v8. (Pubitemid 44391025)
22. Crommelin D, Storm G, Verijk R, et al. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003;266:3-16. (Pubitemid 37249303)
23. Crommelin D, Bermejo T, Bissig M, et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular-weight pharmaceuticals. Eur J Hosp Pharm Sci 2005;11:11-17.
24. Leveque D. Off-label use of anticancer drugs. Lancet Oncol 2008;9:1102-1107.
25. Van Allen E, Miyake T, Gunn N, et al. Off-label use of rituximab in a multipayer insurance system. J Oncol Pract 2011;7:76-79.
26. Hennessy S, Leonard CE, Platt R. Assessing the safety and comparative effectiveness of follow-on biologics (biosimilars) in the United States. Clin Pharmacol Ther 2010;87:157-159.
27. Declerck PJ. Biotherapeutics in the era of Biosimilars. Drug Safety 2007;30:1087-1092.
28. World Health Organization. International Nonproprietary Names. Available at: http://www.who.int/medicines/services/inn/en/. Accessed July 5, 2011.
29. American Medical Association. United States Adopted Names. Available at: http://www.ama-assn.org/ama/pub/physician-resources/medical-science/ united-states-adopted-names-council.page. Accessed June 23, 2011.
30. American Medical Association. How to Apply for a Name. Available at: http://www.ama-assn.org/ama/pub/physician-resources/medical-science/ united-states-adopted-names-council/how-to-apply-for-usan.page? Accessed July 5, 2011.
31. Lambert BL, Lin SJ, Tan HK. Designing safe drug names. Drug Safety 2005;28:495-512. (Pubitemid 41003055)
32. Hoffman JM, Proulx SM. Medication errors caused by confusion of drug names. Drug Safety 2003;26:445-452. (Pubitemid 36629782)
33. Gray T, Bertch K, Galt K, et al. Guidelines for therapeutic interchange-2004. Pharmacotherapy 2005;25:1666-1680.